Form 4: TOI CFO Sells Shares for Tax Obligations

The Oncology Institute's CFO, Robert Ross Carter, sold 247 shares of common stock to cover tax liabilities from an RSU award vesting.

Summary

• Robert Ross Carter, Chief Financial Officer of The Oncology Institute, Inc. (TOI), reported a sale of common stock.
• On January 2, 2026, Mr. Carter sold 247 shares of TOI common stock at a price of $3.56 per share.
• The sale was conducted to cover tax liabilities incurred from the vesting of a Restricted Stock Unit (RSU) award on January 1, 2026.
• Following this transaction, Mr. Carter beneficially owns 235,122 shares of TOI common stock.

Sentiment

Score: 6

Explanation: The transaction is a routine, non-discretionary sale of shares by the CFO to cover tax obligations arising from an RSU award vesting. This is a common practice and does not typically signal a change in management's confidence in the company's future. The reduction in direct ownership is minimal relative to total holdings.

Positives

• The transaction is a routine sale to cover tax liabilities associated with an RSU award, indicating a planned event rather than a discretionary sale based on negative sentiment.

Negatives

• A reduction in direct ownership by a key executive, even if for tax purposes, slightly decreases management's direct equity alignment with shareholders.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• The reporting person used the proceeds of this sale to cover tax liabilities arising from the vesting of an RSU award on January 1, 2026.

Industry Context

This is an insider transaction report, reflecting executive compensation practices common across industries, rather than specific industry trends or competitive dynamics.

Comparison to Industry Standards

• The sale of shares by an executive to cover tax liabilities upon the vesting of Restricted Stock Units (RSUs) is a standard and widely accepted practice in executive compensation across various industries. This transaction aligns with typical compensation structures where equity awards are a significant component.

Related Party Transactions

• The sale of common stock by Robert Ross Carter, the Chief Financial Officer, to cover tax liabilities from an RSU award is a related party transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact. A very small reduction in executive ownership, but for a routine tax purpose.
• Employees: No direct impact.
• Customers/Suppliers/Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of a small number of shares by the CFO to cover tax liabilities associated with an RSU award. Such transactions are common and do not typically indicate a change in the company's fundamentals or management's outlook. Therefore, this specific filing does not provide a basis for a change in investment recommendation; a 'hold' stance is maintained, pending further operational or financial updates.

Keywords

The Oncology Institute, TOI, Form 4, Insider Trading, Robert Ross Carter, CFO, Stock Sale, RSU Vesting, Tax Liabilities, Beneficial Ownership